nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapsone—systemic lupus erythematosus—psoriasis	0.508	1	CtDrD
Dapsone—MPO—Calcipotriol—psoriasis	0.127	0.374	CbGbCtD
Dapsone—CYP2C8—Tazarotene—psoriasis	0.0174	0.0512	CbGbCtD
Dapsone—CYP3A5—Beclomethasone—psoriasis	0.0168	0.0495	CbGbCtD
Dapsone—PTGS2—Triamcinolone—psoriasis	0.0132	0.0389	CbGbCtD
Dapsone—PTGS2—Betamethasone—psoriasis	0.0113	0.0334	CbGbCtD
Dapsone—FMO3—sweat—psoriasis	0.0104	0.598	CbGeAlD
Dapsone—CYP2C8—Cholecalciferol—psoriasis	0.00741	0.0219	CbGbCtD
Dapsone—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.00715	0.0211	CbGbCtD
Dapsone—CYP3A7—Hydrocortisone—psoriasis	0.00715	0.0211	CbGbCtD
Dapsone—CYP3A7—Cyclosporine—psoriasis	0.00675	0.0199	CbGbCtD
Dapsone—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.00675	0.0199	CbGbCtD
Dapsone—CYP3A5—Mycophenolate mofetil—psoriasis	0.00669	0.0197	CbGbCtD
Dapsone—PTGS2—Dexamethasone—psoriasis	0.00658	0.0194	CbGbCtD
Dapsone—CYP2C8—Mycophenolate mofetil—psoriasis	0.00643	0.019	CbGbCtD
Dapsone—CYP2C19—Cholecalciferol—psoriasis	0.00622	0.0184	CbGbCtD
Dapsone—CYP3A4—Calcitriol—psoriasis	0.00584	0.0172	CbGbCtD
Dapsone—CYP3A5—Hydrocortisone—psoriasis	0.00536	0.0158	CbGbCtD
Dapsone—CYP2C9—Cholecalciferol—psoriasis	0.00517	0.0153	CbGbCtD
Dapsone—CYP2C8—Hydrocortisone—psoriasis	0.00516	0.0152	CbGbCtD
Dapsone—CYP3A5—Cyclosporine—psoriasis	0.00507	0.0149	CbGbCtD
Dapsone—CYP2C8—Cyclosporine—psoriasis	0.00487	0.0144	CbGbCtD
Dapsone—CYP3A4—Methoxsalen—psoriasis	0.00454	0.0134	CbGbCtD
Dapsone—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.00445	0.0131	CbGbCtD
Dapsone—CYP3A7—Dexamethasone—psoriasis	0.00445	0.0131	CbGbCtD
Dapsone—CYP2C19—Prednisone—psoriasis	0.00431	0.0127	CbGbCtD
Dapsone—CYP2E1—Dexamethasone—psoriasis	0.00429	0.0127	CbGbCtD
Dapsone—CYP2C19—Cyclosporine—psoriasis	0.00409	0.0121	CbGbCtD
Dapsone—CYP2C9—Cyclosporine—psoriasis	0.0034	0.01	CbGbCtD
Dapsone—CYP3A5—Dexamethasone—psoriasis	0.00334	0.00984	CbGbCtD
Dapsone—CYP2C8—Dexamethasone—psoriasis	0.00321	0.00946	CbGbCtD
Dapsone—CYP3A4—Cholecalciferol—psoriasis	0.00301	0.00887	CbGbCtD
Dapsone—CYP2C19—Dexamethasone—psoriasis	0.00269	0.00794	CbGbCtD
Dapsone—CYP3A4—Mycophenolate mofetil—psoriasis	0.00261	0.00769	CbGbCtD
Dapsone—CYP3A4—Triamcinolone—psoriasis	0.00261	0.00769	CbGbCtD
Dapsone—CYP2C9—Dexamethasone—psoriasis	0.00224	0.0066	CbGbCtD
Dapsone—CYP3A4—Betamethasone—psoriasis	0.00224	0.0066	CbGbCtD
Dapsone—CYP3A4—Prednisolone—psoriasis	0.00221	0.00651	CbGbCtD
Dapsone—CYP3A4—Hydrocortisone—psoriasis	0.00209	0.00617	CbGbCtD
Dapsone—CYP3A4—Prednisone—psoriasis	0.00208	0.00615	CbGbCtD
Dapsone—Application site pain—Tazarotene—psoriasis	0.00201	0.0199	CcSEcCtD
Dapsone—CYP3A4—Cyclosporine—psoriasis	0.00198	0.00583	CbGbCtD
Dapsone—Nerve injury—Fluocinolone Acetonide—psoriasis	0.00193	0.0191	CcSEcCtD
Dapsone—Application site pain—Clobetasol propionate—psoriasis	0.0017	0.0169	CcSEcCtD
Dapsone—Application site reaction—Clobetasol propionate—psoriasis	0.0016	0.0158	CcSEcCtD
Dapsone—Application site pain—Fluocinonide—psoriasis	0.00153	0.0152	CcSEcCtD
Dapsone—PTGS2—skeletal joint—psoriasis	0.00147	0.0846	CbGeAlD
Dapsone—Application site reaction—Fluocinonide—psoriasis	0.00144	0.0143	CcSEcCtD
Dapsone—CYP3A4—Dexamethasone—psoriasis	0.0013	0.00384	CbGbCtD
Dapsone—MPO—endothelium—psoriasis	0.00115	0.0659	CbGeAlD
Dapsone—Skin exfoliation—Calcipotriol—psoriasis	0.00114	0.0113	CcSEcCtD
Dapsone—PTGS2—synovial membrane of synovial joint—psoriasis	0.00112	0.0642	CbGeAlD
Dapsone—Application site burn—Hydrocortisone—psoriasis	0.000953	0.00945	CcSEcCtD
Dapsone—Nerve injury—Prednisolone—psoriasis	0.000936	0.00929	CcSEcCtD
Dapsone—Skin exfoliation—Tazarotene—psoriasis	0.000842	0.00836	CcSEcCtD
Dapsone—Nerve injury—Betamethasone—psoriasis	0.000781	0.00775	CcSEcCtD
Dapsone—Nerve injury—Dexamethasone—psoriasis	0.000781	0.00775	CcSEcCtD
Dapsone—PTGS2—skin epidermis—psoriasis	0.000716	0.0412	CbGeAlD
Dapsone—Localized exfoliation—Triamcinolone—psoriasis	0.000698	0.00692	CcSEcCtD
Dapsone—Nerve injury—Prednisone—psoriasis	0.00068	0.00675	CcSEcCtD
Dapsone—Skin exfoliation—Fluocinonide—psoriasis	0.000644	0.00639	CcSEcCtD
Dapsone—Albuminuria—Calcitriol—psoriasis	0.000636	0.00631	CcSEcCtD
Dapsone—PTGS1—endothelium—psoriasis	0.000544	0.0313	CbGeAlD
Dapsone—Erythema—Calcipotriol—psoriasis	0.000523	0.00519	CcSEcCtD
Dapsone—PTGS2—endothelium—psoriasis	0.00052	0.0299	CbGeAlD
Dapsone—Skin exfoliation—Methoxsalen—psoriasis	0.000508	0.00504	CcSEcCtD
Dapsone—Photosensitivity reaction—Tazarotene—psoriasis	0.000505	0.00501	CcSEcCtD
Dapsone—MPO—skin of body—psoriasis	0.000489	0.0282	CbGeAlD
Dapsone—Proteinuria—Acitretin—psoriasis	0.000481	0.00477	CcSEcCtD
Dapsone—Protein urine present—Acitretin—psoriasis	0.000474	0.0047	CcSEcCtD
Dapsone—Swelling face—Cyclosporine—psoriasis	0.000472	0.00468	CcSEcCtD
Dapsone—Application site pain—Hydrocortisone—psoriasis	0.000454	0.0045	CcSEcCtD
Dapsone—Nasopharyngitis—Beclomethasone—psoriasis	0.000442	0.00438	CcSEcCtD
Dapsone—Nasopharyngitis—Fluocinonide—psoriasis	0.000438	0.00434	CcSEcCtD
Dapsone—Application site reaction—Hydrocortisone—psoriasis	0.000426	0.00422	CcSEcCtD
Dapsone—Skin exfoliation—Acitretin—psoriasis	0.000403	0.004	CcSEcCtD
Dapsone—Application site reaction—Triamcinolone—psoriasis	0.000401	0.00398	CcSEcCtD
Dapsone—Erythema—Tazarotene—psoriasis	0.000386	0.00383	CcSEcCtD
Dapsone—Albuminuria—Mycophenolic acid—psoriasis	0.000372	0.00369	CcSEcCtD
Dapsone—Sinusitis—Beclomethasone—psoriasis	0.000357	0.00354	CcSEcCtD
Dapsone—Pharyngitis—Beclomethasone—psoriasis	0.000339	0.00337	CcSEcCtD
Dapsone—Psychotic disorder—Calcitriol—psoriasis	0.000337	0.00334	CcSEcCtD
Dapsone—FMO3—Metapathway biotransformation—CYP2S1—psoriasis	0.000336	0.0102	CbGpPWpGaD
Dapsone—Erythema—Clobetasol propionate—psoriasis	0.000327	0.00324	CcSEcCtD
Dapsone—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00032	0.00968	CbGpPWpGaD
Dapsone—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.000318	0.157	CbGdCrCtD
Dapsone—Skin exfoliation—Hydroxyurea—psoriasis	0.000317	0.00314	CcSEcCtD
Dapsone—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000316	0.00956	CbGpPWpGaD
Dapsone—Nasopharyngitis—Calcitriol—psoriasis	0.000308	0.00306	CcSEcCtD
Dapsone—Photosensitivity reaction—Methoxsalen—psoriasis	0.000305	0.00303	CcSEcCtD
Dapsone—Erythema—Fluocinonide—psoriasis	0.000295	0.00293	CcSEcCtD
Dapsone—Albuminuria—Mycophenolate mofetil—psoriasis	0.000294	0.00291	CcSEcCtD
Dapsone—Pancreatitis—Calcitriol—psoriasis	0.000292	0.0029	CcSEcCtD
Dapsone—Nasopharyngitis—Fluocinolone Acetonide—psoriasis	0.000273	0.00271	CcSEcCtD
Dapsone—Muscular weakness—Acitretin—psoriasis	0.00027	0.00268	CcSEcCtD
Dapsone—Influenza—Fluocinolone Acetonide—psoriasis	0.000264	0.00262	CcSEcCtD
Dapsone—Cough—Beclomethasone—psoriasis	0.00026	0.00258	CcSEcCtD
Dapsone—Pancreatitis—Acitretin—psoriasis	0.00026	0.00258	CcSEcCtD
Dapsone—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000259	0.00785	CbGpPWpGaD
Dapsone—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000259	0.00784	CbGpPWpGaD
Dapsone—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.000255	0.126	CbGdCrCtD
Dapsone—PTGS1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000252	0.00761	CbGpPWpGaD
Dapsone—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.000247	0.122	CbGdCrCtD
Dapsone—MPO—IL23-mediated signaling events—NFKBIA—psoriasis	0.000243	0.00734	CbGpPWpGaD
Dapsone—MPO—IL23-mediated signaling events—NOS2—psoriasis	0.000243	0.00734	CbGpPWpGaD
Dapsone—Photosensitivity reaction—Acitretin—psoriasis	0.000242	0.0024	CcSEcCtD
Dapsone—Erythema—Methoxsalen—psoriasis	0.000233	0.00231	CcSEcCtD
Dapsone—PTGS1—skin of body—psoriasis	0.000232	0.0134	CbGeAlD
Dapsone—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000232	0.00702	CbGpPWpGaD
Dapsone—Neuropathy peripheral—Acitretin—psoriasis	0.000232	0.0023	CcSEcCtD
Dapsone—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000231	0.007	CbGpPWpGaD
Dapsone—CYP2E1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000229	0.00692	CbGpPWpGaD
Dapsone—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000228	0.00691	CbGpPWpGaD
Dapsone—PTGS2—skin of body—psoriasis	0.000222	0.0128	CbGeAlD
Dapsone—Sinusitis—Acitretin—psoriasis	0.000222	0.0022	CcSEcCtD
Dapsone—Sinusitis—Fluocinolone Acetonide—psoriasis	0.000221	0.00219	CcSEcCtD
Dapsone—FMO3—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000211	0.0064	CbGpPWpGaD
Dapsone—MPO—Folate Metabolism—CAT—psoriasis	0.000211	0.00638	CbGpPWpGaD
Dapsone—Pharyngitis—Acitretin—psoriasis	0.00021	0.00209	CcSEcCtD
Dapsone—Vertigo—Methoxsalen—psoriasis	0.000209	0.00207	CcSEcCtD
Dapsone—Erythema—Calcitriol—psoriasis	0.000207	0.00206	CcSEcCtD
Dapsone—CYP2C18—Biological oxidations—CYP2S1—psoriasis	0.000207	0.00627	CbGpPWpGaD
Dapsone—MPO—Vitamin B12 Metabolism—CRP—psoriasis	0.000206	0.00623	CbGpPWpGaD
Dapsone—CYP2C18—Metapathway biotransformation—CYP2S1—psoriasis	0.000204	0.00619	CbGpPWpGaD
Dapsone—Pancreatitis—Hydroxyurea—psoriasis	0.000204	0.00202	CcSEcCtD
Dapsone—MPO—Vitamin B12 Metabolism—APOE—psoriasis	0.000201	0.0061	CbGpPWpGaD
Dapsone—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.0002	0.00606	CbGpPWpGaD
Dapsone—MPO—IL23-mediated signaling events—TYK2—psoriasis	0.000199	0.00602	CbGpPWpGaD
Dapsone—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000198	0.00598	CbGpPWpGaD
Dapsone—Tinnitus—Acitretin—psoriasis	0.000198	0.00196	CcSEcCtD
Dapsone—Psychotic disorder—Mycophenolic acid—psoriasis	0.000197	0.00195	CcSEcCtD
Dapsone—MPO—Folate Metabolism—IL4—psoriasis	0.000194	0.00587	CbGpPWpGaD
Dapsone—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.000192	0.0949	CbGdCrCtD
Dapsone—Skin exfoliation—Hydrocortisone—psoriasis	0.000191	0.00189	CcSEcCtD
Dapsone—MPO—Vitamin B12 Metabolism—ICAM1—psoriasis	0.000189	0.00573	CbGpPWpGaD
Dapsone—CYP2E1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000188	0.00569	CbGpPWpGaD
Dapsone—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000188	0.00568	CbGpPWpGaD
Dapsone—MPO—IL23-mediated signaling events—IFNG—psoriasis	0.000186	0.00563	CbGpPWpGaD
Dapsone—PTGS1—Overview of nanoparticle effects—CRP—psoriasis	0.000186	0.00562	CbGpPWpGaD
Dapsone—Erythema—Acitretin—psoriasis	0.000185	0.00183	CcSEcCtD
Dapsone—Erythema—Fluocinolone Acetonide—psoriasis	0.000184	0.00183	CcSEcCtD
Dapsone—CYP2E1—tendon—psoriasis	0.000183	0.0106	CbGeAlD
Dapsone—Neuropathy peripheral—Hydroxyurea—psoriasis	0.000182	0.0018	CcSEcCtD
Dapsone—Nasopharyngitis—Mycophenolic acid—psoriasis	0.00018	0.00179	CcSEcCtD
Dapsone—MPO—IL23-mediated signaling events—CD4—psoriasis	0.00018	0.00544	CbGpPWpGaD
Dapsone—Skin exfoliation—Triamcinolone—psoriasis	0.000179	0.00178	CcSEcCtD
Dapsone—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000179	0.00541	CbGpPWpGaD
Dapsone—CYP2C18—Tryptophan metabolism—CAT—psoriasis	0.000179	0.00541	CbGpPWpGaD
Dapsone—Muscular weakness—Mycophenolic acid—psoriasis	0.000178	0.00176	CcSEcCtD
Dapsone—PTGS1—tendon—psoriasis	0.000177	0.0102	CbGeAlD
Dapsone—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000177	0.00534	CbGpPWpGaD
Dapsone—Influenza—Mycophenolic acid—psoriasis	0.000174	0.00173	CcSEcCtD
Dapsone—Vision blurred—Acitretin—psoriasis	0.000174	0.00173	CcSEcCtD
Dapsone—Vision blurred—Fluocinolone Acetonide—psoriasis	0.000173	0.00172	CcSEcCtD
Dapsone—Insomnia—Methoxsalen—psoriasis	0.000172	0.0017	CcSEcCtD
Dapsone—Pancreatitis—Mycophenolic acid—psoriasis	0.000171	0.00169	CcSEcCtD
Dapsone—PTGS2—tendon—psoriasis	0.000169	0.00972	CbGeAlD
Dapsone—MPO—Selenium Micronutrient Network—CAT—psoriasis	0.000168	0.00507	CbGpPWpGaD
Dapsone—MPO—Folate Metabolism—CRP—psoriasis	0.000168	0.00507	CbGpPWpGaD
Dapsone—Headache—Clobetasol propionate—psoriasis	0.000167	0.00166	CcSEcCtD
Dapsone—FMO3—SIDS Susceptibility Pathways—IL13—psoriasis	0.000167	0.00505	CbGpPWpGaD
Dapsone—Vertigo—Fluocinolone Acetonide—psoriasis	0.000165	0.00164	CcSEcCtD
Dapsone—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000163	0.00494	CbGpPWpGaD
Dapsone—Skin exfoliation—Betamethasone—psoriasis	0.000163	0.00162	CcSEcCtD
Dapsone—Skin exfoliation—Dexamethasone—psoriasis	0.000163	0.00162	CcSEcCtD
Dapsone—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000162	0.00492	CbGpPWpGaD
Dapsone—Cough—Acitretin—psoriasis	0.000161	0.0016	CcSEcCtD
Dapsone—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000161	0.00487	CbGpPWpGaD
Dapsone—Cough—Fluocinolone Acetonide—psoriasis	0.000161	0.00159	CcSEcCtD
Dapsone—Psychotic disorder—Mycophenolate mofetil—psoriasis	0.000155	0.00154	CcSEcCtD
Dapsone—MPO—IL23-mediated signaling events—NFKB1—psoriasis	0.000155	0.00469	CbGpPWpGaD
Dapsone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000154	0.00467	CbGpPWpGaD
Dapsone—MPO—Folate Metabolism—ICAM1—psoriasis	0.000154	0.00466	CbGpPWpGaD
Dapsone—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.000154	0.076	CbGdCrCtD
Dapsone—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.000154	0.076	CbGdCrCtD
Dapsone—Insomnia—Calcitriol—psoriasis	0.000153	0.00152	CcSEcCtD
Dapsone—Neuropathy peripheral—Mycophenolic acid—psoriasis	0.000152	0.00151	CcSEcCtD
Dapsone—Headache—Beclomethasone—psoriasis	0.000152	0.00151	CcSEcCtD
Dapsone—Headache—Fluocinonide—psoriasis	0.000151	0.0015	CcSEcCtD
Dapsone—Body temperature increased—Methoxsalen—psoriasis	0.00015	0.00149	CcSEcCtD
Dapsone—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000149	0.0738	CbGdCrCtD
Dapsone—PTGS2—Overview of nanoparticle effects—CRP—psoriasis	0.000147	0.00446	CbGpPWpGaD
Dapsone—Sinusitis—Mycophenolic acid—psoriasis	0.000146	0.00145	CcSEcCtD
Dapsone—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000145	0.00439	CbGpPWpGaD
Dapsone—Erythema—Hydroxyurea—psoriasis	0.000145	0.00144	CcSEcCtD
Dapsone—Nausea—Beclomethasone—psoriasis	0.000144	0.00143	CcSEcCtD
Dapsone—MPO—Vitamin B12 Metabolism—IFNG—psoriasis	0.000144	0.00436	CbGpPWpGaD
Dapsone—Muscular weakness—Cyclosporine—psoriasis	0.000144	0.00143	CcSEcCtD
Dapsone—Skin exfoliation—Prednisone—psoriasis	0.000142	0.00141	CcSEcCtD
Dapsone—Psychotic disorder—Hydrocortisone—psoriasis	0.000142	0.0014	CcSEcCtD
Dapsone—Proteinuria—Methotrexate—psoriasis	0.000141	0.0014	CcSEcCtD
Dapsone—Muscular weakness—Mycophenolate mofetil—psoriasis	0.00014	0.00139	CcSEcCtD
Dapsone—Protein urine present—Methotrexate—psoriasis	0.000139	0.00138	CcSEcCtD
Dapsone—MPO—IL23-mediated signaling events—STAT3—psoriasis	0.000139	0.00421	CbGpPWpGaD
Dapsone—Gastrointestinal pain—Calcitriol—psoriasis	0.000138	0.00137	CcSEcCtD
Dapsone—Pharyngitis—Mycophenolic acid—psoriasis	0.000138	0.00137	CcSEcCtD
Dapsone—Pancreatitis—Cyclosporine—psoriasis	0.000138	0.00137	CcSEcCtD
Dapsone—CYP3A7—Biological oxidations—CYP2S1—psoriasis	0.000138	0.00417	CbGpPWpGaD
Dapsone—Influenza—Mycophenolate mofetil—psoriasis	0.000137	0.00136	CcSEcCtD
Dapsone—Insomnia—Acitretin—psoriasis	0.000136	0.00135	CcSEcCtD
Dapsone—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	0.000136	0.00411	CbGpPWpGaD
Dapsone—Pancreatitis—Mycophenolate mofetil—psoriasis	0.000135	0.00134	CcSEcCtD
Dapsone—Body temperature increased—Calcitriol—psoriasis	0.000134	0.00133	CcSEcCtD
Dapsone—Abdominal pain—Calcitriol—psoriasis	0.000134	0.00133	CcSEcCtD
Dapsone—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.000134	0.00404	CbGpPWpGaD
Dapsone—MPO—Selenium Micronutrient Network—CRP—psoriasis	0.000133	0.00403	CbGpPWpGaD
Dapsone—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000132	0.004	CbGpPWpGaD
Dapsone—Muscular weakness—Prednisolone—psoriasis	0.000131	0.0013	CcSEcCtD
Dapsone—Tinnitus—Mycophenolic acid—psoriasis	0.00013	0.00129	CcSEcCtD
Dapsone—Muscular weakness—Hydrocortisone—psoriasis	0.000128	0.00127	CcSEcCtD
Dapsone—Pancreatitis—Prednisolone—psoriasis	0.000126	0.00125	CcSEcCtD
Dapsone—Gastrointestinal pain—Acitretin—psoriasis	0.000123	0.00122	CcSEcCtD
Dapsone—Neuropathy peripheral—Cyclosporine—psoriasis	0.000123	0.00122	CcSEcCtD
Dapsone—Pancreatitis—Hydrocortisone—psoriasis	0.000123	0.00122	CcSEcCtD
Dapsone—MPO—Selenium Micronutrient Network—ICAM1—psoriasis	0.000122	0.0037	CbGpPWpGaD
Dapsone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—psoriasis	0.000122	0.00368	CbGpPWpGaD
Dapsone—Psychotic disorder—Dexamethasone—psoriasis	0.000121	0.0012	CcSEcCtD
Dapsone—Psychotic disorder—Betamethasone—psoriasis	0.000121	0.0012	CcSEcCtD
Dapsone—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.000121	0.00365	CbGpPWpGaD
Dapsone—MPO—IL23-mediated signaling events—TNF—psoriasis	0.00012	0.00365	CbGpPWpGaD
Dapsone—Muscular weakness—Triamcinolone—psoriasis	0.00012	0.00119	CcSEcCtD
Dapsone—Neuropathy peripheral—Mycophenolate mofetil—psoriasis	0.00012	0.00119	CcSEcCtD
Dapsone—MPO—Vitamin B12 Metabolism—NFKB1—psoriasis	0.00012	0.00363	CbGpPWpGaD
Dapsone—Abdominal pain—Acitretin—psoriasis	0.000119	0.00118	CcSEcCtD
Dapsone—Body temperature increased—Acitretin—psoriasis	0.000119	0.00118	CcSEcCtD
Dapsone—Headache—Methoxsalen—psoriasis	0.000119	0.00118	CcSEcCtD
Dapsone—Body temperature increased—Fluocinolone Acetonide—psoriasis	0.000119	0.00118	CcSEcCtD
Dapsone—Skin exfoliation—Methotrexate—psoriasis	0.000119	0.00118	CcSEcCtD
Dapsone—Influenza—Triamcinolone—psoriasis	0.000118	0.00117	CcSEcCtD
Dapsone—Sinusitis—Cyclosporine—psoriasis	0.000118	0.00117	CcSEcCtD
Dapsone—MPO—Folate Metabolism—IFNG—psoriasis	0.000117	0.00355	CbGpPWpGaD
Dapsone—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.000116	0.0574	CbGdCrCtD
Dapsone—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.000116	0.0574	CbGdCrCtD
Dapsone—Pancreatitis—Triamcinolone—psoriasis	0.000116	0.00115	CcSEcCtD
Dapsone—Sinusitis—Mycophenolate mofetil—psoriasis	0.000115	0.00114	CcSEcCtD
Dapsone—Vision blurred—Mycophenolic acid—psoriasis	0.000114	0.00113	CcSEcCtD
Dapsone—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.000113	0.0561	CbGdCrCtD
Dapsone—Nausea—Methoxsalen—psoriasis	0.000113	0.00112	CcSEcCtD
Dapsone—Neuropathy peripheral—Prednisolone—psoriasis	0.000112	0.00111	CcSEcCtD
Dapsone—Pharyngitis—Cyclosporine—psoriasis	0.000112	0.00111	CcSEcCtD
Dapsone—Neuropathy peripheral—Hydrocortisone—psoriasis	0.000109	0.00109	CcSEcCtD
Dapsone—Pharyngitis—Mycophenolate mofetil—psoriasis	0.000109	0.00108	CcSEcCtD
Dapsone—Muscular weakness—Dexamethasone—psoriasis	0.000109	0.00108	CcSEcCtD
Dapsone—Muscular weakness—Betamethasone—psoriasis	0.000109	0.00108	CcSEcCtD
Dapsone—Vertigo—Mycophenolic acid—psoriasis	0.000109	0.00108	CcSEcCtD
Dapsone—Vomiting—Calcitriol—psoriasis	0.000108	0.00107	CcSEcCtD
Dapsone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000108	0.00325	CbGpPWpGaD
Dapsone—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000106	0.00322	CbGpPWpGaD
Dapsone—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000106	0.00321	CbGpPWpGaD
Dapsone—Headache—Calcitriol—psoriasis	0.000106	0.00105	CcSEcCtD
Dapsone—Cough—Mycophenolic acid—psoriasis	0.000106	0.00105	CcSEcCtD
Dapsone—Psychotic disorder—Prednisone—psoriasis	0.000105	0.00104	CcSEcCtD
Dapsone—Tinnitus—Cyclosporine—psoriasis	0.000105	0.00104	CcSEcCtD
Dapsone—FMO3—SIDS Susceptibility Pathways—IL10—psoriasis	0.000104	0.00316	CbGpPWpGaD
Dapsone—Neuropathy peripheral—Triamcinolone—psoriasis	0.000103	0.00102	CcSEcCtD
Dapsone—Tinnitus—Mycophenolate mofetil—psoriasis	0.000103	0.00102	CcSEcCtD
Dapsone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000102	0.00309	CbGpPWpGaD
Dapsone—Nausea—Calcitriol—psoriasis	0.000101	0.000998	CcSEcCtD
Dapsone—CYP2E1—Biological oxidations—CYP2S1—psoriasis	9.98e-05	0.00302	CbGpPWpGaD
Dapsone—CYP3A5—Biological oxidations—CYP2S1—psoriasis	9.96e-05	0.00301	CbGpPWpGaD
Dapsone—CYP2E1—Metapathway biotransformation—CYP2S1—psoriasis	9.85e-05	0.00298	CbGpPWpGaD
Dapsone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	9.84e-05	0.00298	CbGpPWpGaD
Dapsone—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	9.83e-05	0.00297	CbGpPWpGaD
Dapsone—MPO—Folate Metabolism—NFKB1—psoriasis	9.75e-05	0.00295	CbGpPWpGaD
Dapsone—MPO—IL23-mediated signaling events—IL6—psoriasis	9.72e-05	0.00294	CbGpPWpGaD
Dapsone—Tachycardia—Mycophenolic acid—psoriasis	9.67e-05	0.000959	CcSEcCtD
Dapsone—PTGS2—Overview of nanoparticle effects—CXCL8—psoriasis	9.58e-05	0.0029	CbGpPWpGaD
Dapsone—Vomiting—Acitretin—psoriasis	9.58e-05	0.00095	CcSEcCtD
Dapsone—Vomiting—Fluocinolone Acetonide—psoriasis	9.55e-05	0.000947	CcSEcCtD
Dapsone—Muscular weakness—Prednisone—psoriasis	9.51e-05	0.000943	CcSEcCtD
Dapsone—NAT2—Metabolism—NDUFA5—psoriasis	9.47e-05	0.00287	CbGpPWpGaD
Dapsone—Headache—Acitretin—psoriasis	9.44e-05	0.000936	CcSEcCtD
Dapsone—Headache—Fluocinolone Acetonide—psoriasis	9.41e-05	0.000934	CcSEcCtD
Dapsone—Pharyngitis—Triamcinolone—psoriasis	9.37e-05	0.000929	CcSEcCtD
Dapsone—Neuropathy peripheral—Betamethasone—psoriasis	9.35e-05	0.000928	CcSEcCtD
Dapsone—Neuropathy peripheral—Dexamethasone—psoriasis	9.35e-05	0.000928	CcSEcCtD
Dapsone—Body temperature increased—Hydroxyurea—psoriasis	9.35e-05	0.000927	CcSEcCtD
Dapsone—MPO—C-MYB transcription factor network—CD4—psoriasis	9.33e-05	0.00282	CbGpPWpGaD
Dapsone—MPO—Vitamin B12 Metabolism—TNF—psoriasis	9.32e-05	0.00282	CbGpPWpGaD
Dapsone—MPO—Selenium Micronutrient Network—IFNG—psoriasis	9.31e-05	0.00282	CbGpPWpGaD
Dapsone—Vision blurred—Cyclosporine—psoriasis	9.25e-05	0.000918	CcSEcCtD
Dapsone—Pancreatitis—Prednisone—psoriasis	9.14e-05	0.000906	CcSEcCtD
Dapsone—Insomnia—Mycophenolic acid—psoriasis	8.96e-05	0.000889	CcSEcCtD
Dapsone—Nausea—Acitretin—psoriasis	8.95e-05	0.000888	CcSEcCtD
Dapsone—Erythema—Prednisolone—psoriasis	8.94e-05	0.000886	CcSEcCtD
Dapsone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	8.93e-05	0.0027	CbGpPWpGaD
Dapsone—Nausea—Fluocinolone Acetonide—psoriasis	8.92e-05	0.000885	CcSEcCtD
Dapsone—CYP2C18—FOXA1 transcription factor network—JUN—psoriasis	8.9e-05	0.00269	CbGpPWpGaD
Dapsone—Vertigo—Cyclosporine—psoriasis	8.82e-05	0.000875	CcSEcCtD
Dapsone—Erythema—Hydrocortisone—psoriasis	8.73e-05	0.000866	CcSEcCtD
Dapsone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	8.72e-05	0.00264	CbGpPWpGaD
Dapsone—CYP2C8—Biological oxidations—CYP2S1—psoriasis	8.63e-05	0.00261	CbGpPWpGaD
Dapsone—CYP2E1—Tryptophan metabolism—CAT—psoriasis	8.61e-05	0.00261	CbGpPWpGaD
Dapsone—Vertigo—Mycophenolate mofetil—psoriasis	8.61e-05	0.000854	CcSEcCtD
Dapsone—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	8.6e-05	0.0026	CbGpPWpGaD
Dapsone—Cough—Cyclosporine—psoriasis	8.57e-05	0.00085	CcSEcCtD
Dapsone—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	8.51e-05	0.00258	CbGpPWpGaD
Dapsone—Vision blurred—Prednisolone—psoriasis	8.42e-05	0.000835	CcSEcCtD
Dapsone—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	8.4e-05	0.00254	CbGpPWpGaD
Dapsone—Cough—Mycophenolate mofetil—psoriasis	8.36e-05	0.000829	CcSEcCtD
Dapsone—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	8.24e-05	0.00249	CbGpPWpGaD
Dapsone—Erythema—Triamcinolone—psoriasis	8.22e-05	0.000815	CcSEcCtD
Dapsone—Neuropathy peripheral—Prednisone—psoriasis	8.14e-05	0.000808	CcSEcCtD
Dapsone—Gastrointestinal pain—Mycophenolic acid—psoriasis	8.1e-05	0.000804	CcSEcCtD
Dapsone—NAT2—Metabolism—CYP2S1—psoriasis	8.05e-05	0.00244	CbGpPWpGaD
Dapsone—Vertigo—Prednisolone—psoriasis	8.03e-05	0.000796	CcSEcCtD
Dapsone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	7.86e-05	0.00238	CbGpPWpGaD
Dapsone—Vertigo—Hydrocortisone—psoriasis	7.84e-05	0.000778	CcSEcCtD
Dapsone—Body temperature increased—Mycophenolic acid—psoriasis	7.83e-05	0.000777	CcSEcCtD
Dapsone—Abdominal pain—Mycophenolic acid—psoriasis	7.83e-05	0.000777	CcSEcCtD
Dapsone—PTGS2—S1P1 pathway—VEGFA—psoriasis	7.78e-05	0.00236	CbGpPWpGaD
Dapsone—MPO—Selenium Micronutrient Network—NFKB1—psoriasis	7.75e-05	0.00234	CbGpPWpGaD
Dapsone—CYP2C19—Biological oxidations—CYP2S1—psoriasis	7.7e-05	0.00233	CbGpPWpGaD
Dapsone—Pancreatitis—Methotrexate—psoriasis	7.64e-05	0.000757	CcSEcCtD
Dapsone—Tachycardia—Mycophenolate mofetil—psoriasis	7.63e-05	0.000757	CcSEcCtD
Dapsone—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	7.6e-05	0.0023	CbGpPWpGaD
Dapsone—MPO—Folate Metabolism—TNF—psoriasis	7.58e-05	0.00229	CbGpPWpGaD
Dapsone—MPO—Vitamin B12 Metabolism—IL6—psoriasis	7.52e-05	0.00228	CbGpPWpGaD
Dapsone—Vomiting—Hydroxyurea—psoriasis	7.52e-05	0.000746	CcSEcCtD
Dapsone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.49e-05	0.00227	CbGpPWpGaD
Dapsone—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	7.47e-05	0.00226	CbGpPWpGaD
Dapsone—Erythema—Betamethasone—psoriasis	7.46e-05	0.00074	CcSEcCtD
Dapsone—Erythema—Dexamethasone—psoriasis	7.46e-05	0.00074	CcSEcCtD
Dapsone—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.42e-05	0.00225	CbGpPWpGaD
Dapsone—Headache—Hydroxyurea—psoriasis	7.41e-05	0.000735	CcSEcCtD
Dapsone—Vertigo—Triamcinolone—psoriasis	7.38e-05	0.000732	CcSEcCtD
Dapsone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—psoriasis	7.35e-05	0.00222	CbGpPWpGaD
Dapsone—Insomnia—Cyclosporine—psoriasis	7.25e-05	0.000719	CcSEcCtD
Dapsone—Cough—Triamcinolone—psoriasis	7.17e-05	0.000711	CcSEcCtD
Dapsone—Tachycardia—Prednisolone—psoriasis	7.12e-05	0.000706	CcSEcCtD
Dapsone—Photosensitivity reaction—Methotrexate—psoriasis	7.11e-05	0.000705	CcSEcCtD
Dapsone—Insomnia—Mycophenolate mofetil—psoriasis	7.07e-05	0.000701	CcSEcCtD
Dapsone—Nausea—Hydroxyurea—psoriasis	7.03e-05	0.000697	CcSEcCtD
Dapsone—CYP2C9—Biological oxidations—CYP2S1—psoriasis	7.02e-05	0.00213	CbGpPWpGaD
Dapsone—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	7e-05	0.0346	CbGdCrCtD
Dapsone—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	7e-05	0.0346	CbGdCrCtD
Dapsone—Tachycardia—Hydrocortisone—psoriasis	6.95e-05	0.00069	CcSEcCtD
Dapsone—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	6.93e-05	0.0021	CbGpPWpGaD
Dapsone—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	6.86e-05	0.00208	CbGpPWpGaD
Dapsone—FMO3—Metabolism—NDUFA5—psoriasis	6.85e-05	0.00207	CbGpPWpGaD
Dapsone—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	6.84e-05	0.0338	CbGdCrCtD
Dapsone—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	6.78e-05	0.00205	CbGpPWpGaD
Dapsone—Vertigo—Betamethasone—psoriasis	6.7e-05	0.000664	CcSEcCtD
Dapsone—Vertigo—Dexamethasone—psoriasis	6.7e-05	0.000664	CcSEcCtD
Dapsone—MPO—Folate Metabolism—TP53—psoriasis	6.69e-05	0.00202	CbGpPWpGaD
Dapsone—PTGS2—Overview of nanoparticle effects—TNF—psoriasis	6.67e-05	0.00202	CbGpPWpGaD
Dapsone—Insomnia—Prednisolone—psoriasis	6.6e-05	0.000654	CcSEcCtD
Dapsone—Gastrointestinal pain—Cyclosporine—psoriasis	6.55e-05	0.00065	CcSEcCtD
Dapsone—Tachycardia—Triamcinolone—psoriasis	6.55e-05	0.000649	CcSEcCtD
Dapsone—Erythema—Prednisone—psoriasis	6.49e-05	0.000644	CcSEcCtD
Dapsone—Insomnia—Hydrocortisone—psoriasis	6.44e-05	0.000639	CcSEcCtD
Dapsone—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	6.39e-05	0.000634	CcSEcCtD
Dapsone—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—psoriasis	6.35e-05	0.00192	CbGpPWpGaD
Dapsone—Body temperature increased—Cyclosporine—psoriasis	6.34e-05	0.000628	CcSEcCtD
Dapsone—Abdominal pain—Cyclosporine—psoriasis	6.34e-05	0.000628	CcSEcCtD
Dapsone—Vomiting—Mycophenolic acid—psoriasis	6.3e-05	0.000625	CcSEcCtD
Dapsone—Headache—Mycophenolic acid—psoriasis	6.21e-05	0.000616	CcSEcCtD
Dapsone—PTGS2—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	6.19e-05	0.00187	CbGpPWpGaD
Dapsone—Pharyngitis—Methotrexate—psoriasis	6.19e-05	0.000614	CcSEcCtD
Dapsone—Abdominal pain—Mycophenolate mofetil—psoriasis	6.18e-05	0.000613	CcSEcCtD
Dapsone—Body temperature increased—Mycophenolate mofetil—psoriasis	6.18e-05	0.000613	CcSEcCtD
Dapsone—MPO—Folate Metabolism—IL6—psoriasis	6.12e-05	0.00185	CbGpPWpGaD
Dapsone—Vision blurred—Prednisone—psoriasis	6.12e-05	0.000607	CcSEcCtD
Dapsone—Insomnia—Triamcinolone—psoriasis	6.07e-05	0.000602	CcSEcCtD
Dapsone—MPO—Selenium Micronutrient Network—TNF—psoriasis	6.02e-05	0.00182	CbGpPWpGaD
Dapsone—Tachycardia—Betamethasone—psoriasis	5.94e-05	0.000589	CcSEcCtD
Dapsone—Tachycardia—Dexamethasone—psoriasis	5.94e-05	0.000589	CcSEcCtD
Dapsone—Nausea—Mycophenolic acid—psoriasis	5.88e-05	0.000584	CcSEcCtD
Dapsone—Vertigo—Prednisone—psoriasis	5.83e-05	0.000579	CcSEcCtD
Dapsone—Gastrointestinal pain—Hydrocortisone—psoriasis	5.82e-05	0.000578	CcSEcCtD
Dapsone—FMO3—Metabolism—CYP2S1—psoriasis	5.82e-05	0.00176	CbGpPWpGaD
Dapsone—Tinnitus—Methotrexate—psoriasis	5.81e-05	0.000577	CcSEcCtD
Dapsone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—psoriasis	5.79e-05	0.00175	CbGpPWpGaD
Dapsone—FMO3—SIDS Susceptibility Pathways—CXCL8—psoriasis	5.71e-05	0.00173	CbGpPWpGaD
Dapsone—Abdominal pain—Hydrocortisone—psoriasis	5.63e-05	0.000558	CcSEcCtD
Dapsone—Body temperature increased—Hydrocortisone—psoriasis	5.63e-05	0.000558	CcSEcCtD
Dapsone—Insomnia—Dexamethasone—psoriasis	5.5e-05	0.000546	CcSEcCtD
Dapsone—Insomnia—Betamethasone—psoriasis	5.5e-05	0.000546	CcSEcCtD
Dapsone—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	5.47e-05	0.00165	CbGpPWpGaD
Dapsone—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	5.45e-05	0.00165	CbGpPWpGaD
Dapsone—PTGS2—Selenium Micronutrient Network—CAT—psoriasis	5.45e-05	0.00165	CbGpPWpGaD
Dapsone—Erythema—Methotrexate—psoriasis	5.43e-05	0.000538	CcSEcCtD
Dapsone—PTGS2—Overview of nanoparticle effects—IL6—psoriasis	5.38e-05	0.00163	CbGpPWpGaD
Dapsone—FMO3—SIDS Susceptibility Pathways—JUN—psoriasis	5.31e-05	0.00161	CbGpPWpGaD
Dapsone—Body temperature increased—Triamcinolone—psoriasis	5.3e-05	0.000526	CcSEcCtD
Dapsone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.22e-05	0.00158	CbGpPWpGaD
Dapsone—Tachycardia—Prednisone—psoriasis	5.17e-05	0.000513	CcSEcCtD
Dapsone—Vision blurred—Methotrexate—psoriasis	5.11e-05	0.000507	CcSEcCtD
Dapsone—FMO3—SIDS Susceptibility Pathways—NFKB1—psoriasis	5.11e-05	0.00155	CbGpPWpGaD
Dapsone—Vomiting—Cyclosporine—psoriasis	5.1e-05	0.000505	CcSEcCtD
Dapsone—Headache—Cyclosporine—psoriasis	5.02e-05	0.000498	CcSEcCtD
Dapsone—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	5.01e-05	0.00151	CbGpPWpGaD
Dapsone—Gastrointestinal pain—Betamethasone—psoriasis	4.98e-05	0.000494	CcSEcCtD
Dapsone—Gastrointestinal pain—Dexamethasone—psoriasis	4.98e-05	0.000494	CcSEcCtD
Dapsone—Vomiting—Mycophenolate mofetil—psoriasis	4.97e-05	0.000493	CcSEcCtD
Dapsone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	4.94e-05	0.00149	CbGpPWpGaD
Dapsone—Headache—Mycophenolate mofetil—psoriasis	4.9e-05	0.000486	CcSEcCtD
Dapsone—Vertigo—Methotrexate—psoriasis	4.88e-05	0.000484	CcSEcCtD
Dapsone—MPO—Selenium Micronutrient Network—IL6—psoriasis	4.86e-05	0.00147	CbGpPWpGaD
Dapsone—Abdominal pain—Betamethasone—psoriasis	4.81e-05	0.000477	CcSEcCtD
Dapsone—Abdominal pain—Dexamethasone—psoriasis	4.81e-05	0.000477	CcSEcCtD
Dapsone—Body temperature increased—Dexamethasone—psoriasis	4.81e-05	0.000477	CcSEcCtD
Dapsone—Body temperature increased—Betamethasone—psoriasis	4.81e-05	0.000477	CcSEcCtD
Dapsone—Insomnia—Prednisone—psoriasis	4.79e-05	0.000475	CcSEcCtD
Dapsone—Nausea—Cyclosporine—psoriasis	4.76e-05	0.000472	CcSEcCtD
Dapsone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	4.75e-05	0.00144	CbGpPWpGaD
Dapsone—Cough—Methotrexate—psoriasis	4.74e-05	0.00047	CcSEcCtD
Dapsone—Nausea—Mycophenolate mofetil—psoriasis	4.64e-05	0.000461	CcSEcCtD
Dapsone—FMO3—SIDS Susceptibility Pathways—VEGFA—psoriasis	4.64e-05	0.0014	CbGpPWpGaD
Dapsone—CYP3A4—Biological oxidations—CYP2S1—psoriasis	4.63e-05	0.0014	CbGpPWpGaD
Dapsone—Headache—Prednisolone—psoriasis	4.57e-05	0.000453	CcSEcCtD
Dapsone—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	4.57e-05	0.00138	CbGpPWpGaD
Dapsone—Vomiting—Hydrocortisone—psoriasis	4.53e-05	0.000449	CcSEcCtD
Dapsone—Headache—Hydrocortisone—psoriasis	4.46e-05	0.000443	CcSEcCtD
Dapsone—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	4.44e-05	0.00134	CbGpPWpGaD
Dapsone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	4.42e-05	0.00134	CbGpPWpGaD
Dapsone—Gastrointestinal pain—Prednisone—psoriasis	4.33e-05	0.00043	CcSEcCtD
Dapsone—Nausea—Prednisolone—psoriasis	4.33e-05	0.00043	CcSEcCtD
Dapsone—PTGS2—Selenium Micronutrient Network—CRP—psoriasis	4.32e-05	0.00131	CbGpPWpGaD
Dapsone—Vomiting—Triamcinolone—psoriasis	4.26e-05	0.000423	CcSEcCtD
Dapsone—Nausea—Hydrocortisone—psoriasis	4.23e-05	0.00042	CcSEcCtD
Dapsone—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	4.23e-05	0.00128	CbGpPWpGaD
Dapsone—Headache—Triamcinolone—psoriasis	4.2e-05	0.000417	CcSEcCtD
Dapsone—Abdominal pain—Prednisone—psoriasis	4.19e-05	0.000416	CcSEcCtD
Dapsone—Body temperature increased—Prednisone—psoriasis	4.19e-05	0.000416	CcSEcCtD
Dapsone—CYP2C18—Metabolism—NDUFA5—psoriasis	4.17e-05	0.00126	CbGpPWpGaD
Dapsone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	4.11e-05	0.00124	CbGpPWpGaD
Dapsone—Insomnia—Methotrexate—psoriasis	4.01e-05	0.000397	CcSEcCtD
Dapsone—CYP3A4—Tryptophan metabolism—CAT—psoriasis	4e-05	0.00121	CbGpPWpGaD
Dapsone—Nausea—Triamcinolone—psoriasis	3.98e-05	0.000395	CcSEcCtD
Dapsone—FMO3—SIDS Susceptibility Pathways—TNF—psoriasis	3.97e-05	0.0012	CbGpPWpGaD
Dapsone—PTGS2—Selenium Micronutrient Network—ICAM1—psoriasis	3.97e-05	0.0012	CbGpPWpGaD
Dapsone—PTGS2—Spinal Cord Injury—IL4—psoriasis	3.96e-05	0.0012	CbGpPWpGaD
Dapsone—NAT2—Metabolism—CARM1—psoriasis	3.93e-05	0.00119	CbGpPWpGaD
Dapsone—Vomiting—Dexamethasone—psoriasis	3.87e-05	0.000384	CcSEcCtD
Dapsone—Vomiting—Betamethasone—psoriasis	3.87e-05	0.000384	CcSEcCtD
Dapsone—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.84e-05	0.00116	CbGpPWpGaD
Dapsone—Headache—Dexamethasone—psoriasis	3.81e-05	0.000378	CcSEcCtD
Dapsone—Headache—Betamethasone—psoriasis	3.81e-05	0.000378	CcSEcCtD
Dapsone—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	3.81e-05	0.00115	CbGpPWpGaD
Dapsone—Gastrointestinal pain—Methotrexate—psoriasis	3.62e-05	0.000359	CcSEcCtD
Dapsone—Nausea—Dexamethasone—psoriasis	3.61e-05	0.000359	CcSEcCtD
Dapsone—Nausea—Betamethasone—psoriasis	3.61e-05	0.000359	CcSEcCtD
Dapsone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	3.61e-05	0.00109	CbGpPWpGaD
Dapsone—CYP2C18—Metabolism—CYP2S1—psoriasis	3.55e-05	0.00107	CbGpPWpGaD
Dapsone—Abdominal pain—Methotrexate—psoriasis	3.5e-05	0.000347	CcSEcCtD
Dapsone—Body temperature increased—Methotrexate—psoriasis	3.5e-05	0.000347	CcSEcCtD
Dapsone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.44e-05	0.00104	CbGpPWpGaD
Dapsone—Vomiting—Prednisone—psoriasis	3.37e-05	0.000334	CcSEcCtD
Dapsone—PTGS2—Spinal Cord Injury—LEP—psoriasis	3.35e-05	0.00101	CbGpPWpGaD
Dapsone—Headache—Prednisone—psoriasis	3.32e-05	0.000329	CcSEcCtD
Dapsone—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.29e-05	0.000995	CbGpPWpGaD
Dapsone—FMO3—SIDS Susceptibility Pathways—IL6—psoriasis	3.21e-05	0.000971	CbGpPWpGaD
Dapsone—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	3.17e-05	0.000959	CbGpPWpGaD
Dapsone—Nausea—Prednisone—psoriasis	3.15e-05	0.000312	CcSEcCtD
Dapsone—PTGS2—Spinal Cord Injury—ICAM1—psoriasis	3.14e-05	0.000951	CbGpPWpGaD
Dapsone—PTGS2—Spinal Cord Injury—NOS2—psoriasis	3.12e-05	0.000943	CbGpPWpGaD
Dapsone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	3.08e-05	0.000931	CbGpPWpGaD
Dapsone—PTGS2—C-MYB transcription factor network—CD4—psoriasis	3.03e-05	0.000917	CbGpPWpGaD
Dapsone—PTGS2—Selenium Micronutrient Network—IFNG—psoriasis	3.02e-05	0.000915	CbGpPWpGaD
Dapsone—FMO3—Metabolism—CARM1—psoriasis	2.84e-05	0.00086	CbGpPWpGaD
Dapsone—Vomiting—Methotrexate—psoriasis	2.82e-05	0.000279	CcSEcCtD
Dapsone—Headache—Methotrexate—psoriasis	2.77e-05	0.000275	CcSEcCtD
Dapsone—CYP3A7—Metabolism—NDUFA5—psoriasis	2.77e-05	0.000839	CbGpPWpGaD
Dapsone—PTGS1—Metabolism—NDUFA5—psoriasis	2.69e-05	0.000813	CbGpPWpGaD
Dapsone—Nausea—Methotrexate—psoriasis	2.63e-05	0.000261	CcSEcCtD
Dapsone—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.52e-05	0.000764	CbGpPWpGaD
Dapsone—PTGS2—Selenium Micronutrient Network—NFKB1—psoriasis	2.52e-05	0.000761	CbGpPWpGaD
Dapsone—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.51e-05	0.000758	CbGpPWpGaD
Dapsone—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	2.47e-05	0.000746	CbGpPWpGaD
Dapsone—NAT2—Metabolism—CAT—psoriasis	2.42e-05	0.000732	CbGpPWpGaD
Dapsone—PTGS2—Spinal Cord Injury—IFNG—psoriasis	2.39e-05	0.000724	CbGpPWpGaD
Dapsone—CYP3A7—Metabolism—CYP2S1—psoriasis	2.36e-05	0.000713	CbGpPWpGaD
Dapsone—PTGS1—Metabolism—CYP2S1—psoriasis	2.28e-05	0.000691	CbGpPWpGaD
Dapsone—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	2.22e-05	0.000673	CbGpPWpGaD
Dapsone—PTGS2—Metabolism—NDUFA5—psoriasis	2.13e-05	0.000645	CbGpPWpGaD
Dapsone—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.12e-05	0.000642	CbGpPWpGaD
Dapsone—CYP2E1—Metabolism—NDUFA5—psoriasis	2.01e-05	0.000608	CbGpPWpGaD
Dapsone—CYP3A5—Metabolism—NDUFA5—psoriasis	2e-05	0.000606	CbGpPWpGaD
Dapsone—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	1.99e-05	0.000602	CbGpPWpGaD
Dapsone—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.99e-05	0.000602	CbGpPWpGaD
Dapsone—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	1.96e-05	0.000592	CbGpPWpGaD
Dapsone—NAT2—Metabolism—APOE—psoriasis	1.88e-05	0.000569	CbGpPWpGaD
Dapsone—PTGS2—Metabolism—CYP2S1—psoriasis	1.81e-05	0.000549	CbGpPWpGaD
Dapsone—FMO3—Metabolism—CAT—psoriasis	1.75e-05	0.000529	CbGpPWpGaD
Dapsone—CYP2C8—Metabolism—NDUFA5—psoriasis	1.74e-05	0.000525	CbGpPWpGaD
Dapsone—CYP2C18—Metabolism—CARM1—psoriasis	1.73e-05	0.000524	CbGpPWpGaD
Dapsone—CYP2E1—Metabolism—CYP2S1—psoriasis	1.71e-05	0.000517	CbGpPWpGaD
Dapsone—CYP3A5—Metabolism—CYP2S1—psoriasis	1.7e-05	0.000516	CbGpPWpGaD
Dapsone—NAT2—Metabolism—PPARG—psoriasis	1.64e-05	0.000495	CbGpPWpGaD
Dapsone—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.62e-05	0.00049	CbGpPWpGaD
Dapsone—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	1.58e-05	0.000478	CbGpPWpGaD
Dapsone—CYP2C19—Metabolism—NDUFA5—psoriasis	1.55e-05	0.000469	CbGpPWpGaD
Dapsone—PTGS2—Spinal Cord Injury—TNF—psoriasis	1.55e-05	0.000468	CbGpPWpGaD
Dapsone—CYP2C8—Metabolism—CYP2S1—psoriasis	1.48e-05	0.000447	CbGpPWpGaD
Dapsone—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.44e-05	0.000437	CbGpPWpGaD
Dapsone—CYP2C9—Metabolism—NDUFA5—psoriasis	1.41e-05	0.000427	CbGpPWpGaD
Dapsone—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.41e-05	0.000426	CbGpPWpGaD
Dapsone—PTGS2—Spinal Cord Injury—TP53—psoriasis	1.36e-05	0.000413	CbGpPWpGaD
Dapsone—FMO3—Metabolism—APOE—psoriasis	1.36e-05	0.000411	CbGpPWpGaD
Dapsone—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.35e-05	0.00041	CbGpPWpGaD
Dapsone—CYP2C19—Metabolism—CYP2S1—psoriasis	1.32e-05	0.000399	CbGpPWpGaD
Dapsone—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.32e-05	0.000399	CbGpPWpGaD
Dapsone—PTGS2—Spinal Cord Injury—IL6—psoriasis	1.25e-05	0.000378	CbGpPWpGaD
Dapsone—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.23e-05	0.000372	CbGpPWpGaD
Dapsone—CYP2C9—Metabolism—CYP2S1—psoriasis	1.2e-05	0.000363	CbGpPWpGaD
Dapsone—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.2e-05	0.000362	CbGpPWpGaD
Dapsone—FMO3—Metabolism—PPARG—psoriasis	1.18e-05	0.000358	CbGpPWpGaD
Dapsone—CYP3A7—Metabolism—CARM1—psoriasis	1.15e-05	0.000348	CbGpPWpGaD
Dapsone—PTGS1—Metabolism—CARM1—psoriasis	1.12e-05	0.000338	CbGpPWpGaD
Dapsone—CYP2C18—Metabolism—CAT—psoriasis	1.07e-05	0.000322	CbGpPWpGaD
Dapsone—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.05e-05	0.000319	CbGpPWpGaD
Dapsone—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.04e-05	0.000316	CbGpPWpGaD
Dapsone—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.51e-06	0.000288	CbGpPWpGaD
Dapsone—CYP3A4—Metabolism—NDUFA5—psoriasis	9.32e-06	0.000282	CbGpPWpGaD
Dapsone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	9.28e-06	0.000281	CbGpPWpGaD
Dapsone—PTGS2—Metabolism—CARM1—psoriasis	8.86e-06	0.000268	CbGpPWpGaD
Dapsone—CYP2E1—Metabolism—CARM1—psoriasis	8.34e-06	0.000252	CbGpPWpGaD
Dapsone—CYP3A5—Metabolism—CARM1—psoriasis	8.32e-06	0.000252	CbGpPWpGaD
Dapsone—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.28e-06	0.000251	CbGpPWpGaD
Dapsone—CYP2C18—Metabolism—APOE—psoriasis	8.28e-06	0.00025	CbGpPWpGaD
Dapsone—CYP3A4—Metabolism—CYP2S1—psoriasis	7.92e-06	0.00024	CbGpPWpGaD
Dapsone—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.73e-06	0.000234	CbGpPWpGaD
Dapsone—CYP2C18—Metabolism—PPARG—psoriasis	7.21e-06	0.000218	CbGpPWpGaD
Dapsone—CYP2C8—Metabolism—CARM1—psoriasis	7.21e-06	0.000218	CbGpPWpGaD
Dapsone—CYP3A7—Metabolism—CAT—psoriasis	7.08e-06	0.000214	CbGpPWpGaD
Dapsone—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.9e-06	0.000209	CbGpPWpGaD
Dapsone—PTGS1—Metabolism—CAT—psoriasis	6.86e-06	0.000208	CbGpPWpGaD
Dapsone—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.74e-06	0.000204	CbGpPWpGaD
Dapsone—CYP2C19—Metabolism—CARM1—psoriasis	6.43e-06	0.000195	CbGpPWpGaD
Dapsone—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.29e-06	0.00019	CbGpPWpGaD
Dapsone—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.01e-06	0.000182	CbGpPWpGaD
Dapsone—CYP2C9—Metabolism—CARM1—psoriasis	5.87e-06	0.000177	CbGpPWpGaD
Dapsone—CYP3A7—Metabolism—APOE—psoriasis	5.5e-06	0.000166	CbGpPWpGaD
Dapsone—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.48e-06	0.000166	CbGpPWpGaD
Dapsone—PTGS2—Metabolism—CAT—psoriasis	5.45e-06	0.000165	CbGpPWpGaD
Dapsone—PTGS2—Disease—HLA-A—psoriasis	5.41e-06	0.000164	CbGpPWpGaD
Dapsone—PTGS1—Metabolism—APOE—psoriasis	5.33e-06	0.000161	CbGpPWpGaD
Dapsone—CYP2E1—Metabolism—CAT—psoriasis	5.13e-06	0.000155	CbGpPWpGaD
Dapsone—CYP3A5—Metabolism—CAT—psoriasis	5.12e-06	0.000155	CbGpPWpGaD
Dapsone—PTGS2—Disease—APOE—psoriasis	5.05e-06	0.000153	CbGpPWpGaD
Dapsone—CYP3A7—Metabolism—PPARG—psoriasis	4.79e-06	0.000145	CbGpPWpGaD
Dapsone—PTGS2—Disease—NOS2—psoriasis	4.71e-06	0.000143	CbGpPWpGaD
Dapsone—PTGS1—Metabolism—PPARG—psoriasis	4.64e-06	0.000141	CbGpPWpGaD
Dapsone—CYP2C8—Metabolism—CAT—psoriasis	4.43e-06	0.000134	CbGpPWpGaD
Dapsone—PTGS2—Metabolism—APOE—psoriasis	4.23e-06	0.000128	CbGpPWpGaD
Dapsone—CYP2E1—Metabolism—APOE—psoriasis	3.98e-06	0.000121	CbGpPWpGaD
Dapsone—CYP3A5—Metabolism—APOE—psoriasis	3.98e-06	0.00012	CbGpPWpGaD
Dapsone—CYP2C19—Metabolism—CAT—psoriasis	3.96e-06	0.00012	CbGpPWpGaD
Dapsone—CYP3A4—Metabolism—CARM1—psoriasis	3.87e-06	0.000117	CbGpPWpGaD
Dapsone—PTGS2—Disease—TYK2—psoriasis	3.86e-06	0.000117	CbGpPWpGaD
Dapsone—PTGS2—Metabolism—PPARG—psoriasis	3.69e-06	0.000112	CbGpPWpGaD
Dapsone—CYP2C9—Metabolism—CAT—psoriasis	3.61e-06	0.000109	CbGpPWpGaD
Dapsone—PTGS2—Disease—CD4—psoriasis	3.49e-06	0.000106	CbGpPWpGaD
Dapsone—CYP2E1—Metabolism—PPARG—psoriasis	3.47e-06	0.000105	CbGpPWpGaD
Dapsone—CYP3A5—Metabolism—PPARG—psoriasis	3.46e-06	0.000105	CbGpPWpGaD
Dapsone—CYP2C8—Metabolism—APOE—psoriasis	3.44e-06	0.000104	CbGpPWpGaD
Dapsone—CYP2C19—Metabolism—APOE—psoriasis	3.07e-06	9.3e-05	CbGpPWpGaD
Dapsone—CYP2C8—Metabolism—PPARG—psoriasis	3e-06	9.08e-05	CbGpPWpGaD
Dapsone—CYP2C9—Metabolism—APOE—psoriasis	2.8e-06	8.48e-05	CbGpPWpGaD
Dapsone—PTGS2—Disease—STAT3—psoriasis	2.7e-06	8.17e-05	CbGpPWpGaD
Dapsone—CYP2C19—Metabolism—PPARG—psoriasis	2.68e-06	8.1e-05	CbGpPWpGaD
Dapsone—CYP2C9—Metabolism—PPARG—psoriasis	2.44e-06	7.39e-05	CbGpPWpGaD
Dapsone—CYP3A4—Metabolism—CAT—psoriasis	2.38e-06	7.2e-05	CbGpPWpGaD
Dapsone—PTGS2—Disease—IL6—psoriasis	1.89e-06	5.71e-05	CbGpPWpGaD
Dapsone—CYP3A4—Metabolism—APOE—psoriasis	1.85e-06	5.59e-05	CbGpPWpGaD
Dapsone—CYP3A4—Metabolism—PPARG—psoriasis	1.61e-06	4.87e-05	CbGpPWpGaD
